Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte (Nasdaq: VCYT) will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time. A live audio webcast and a 90-day replay will be accessible via the company’s investor relations website.
Veracyte (Nasdaq: VCYT) reported second quarter 2026 total revenue of $150.3 million, up 15% year-over-year, with testing revenue up 19% to $145.7 million. Growth was driven by Decipher revenue of $91.9 million (+20%) and Afirma revenue of $51.2 million (+18%), on testing volume growth of 14% to 48,389 tests.
The company generated GAAP net income of $25.5 million (17.0% margin) and adjusted EBITDA of $44.0 million (29.2% margin), and ended June 30, 2026 with $485.2 million in cash, cash equivalents and short-term investments. Veracyte launched the Prosigna Breast Test in the U.S. and the TrueMRD Monitoring Test for MIBC, and obtained Medicare coverage for TrueMRD. Total gross margin increased to 72% (non-GAAP 75%), while operating expenses declined on a GAAP basis to $85.6 million.
For full-year 2026, Veracyte raised total revenue guidance to $590–$596 million (14–15% growth) and testing revenue guidance to $576–$582 million (17–18% growth), and continues to expect adjusted EBITDA margin to exceed 26%.
Veracyte (Nasdaq: VCYT) will participate in two upcoming investor events: the Canaccord Genuity 46th Annual Growth Conference in Boston, with a fireside chat on Tuesday, August 11 at 10:30 a.m. Eastern Time, and the Morgan Stanley 24th Annual Global Healthcare Conference in New York, with a fireside chat on Tuesday, September 15 at 5:35 p.m. Eastern Time. Live audio webcasts and 90-day replays for both presentations will be accessible via Veracyte’s investor relations website.
Veracyte (Nasdaq:VCYT) will release its second quarter 2026 financial results after the market close on Thursday, July 30, 2026. Management will host a conference call and live webcast at 4:30 p.m. Eastern Time to discuss results and provide a business update.
The webcast will be accessible through Veracyte’s investor relations website, with a replay available after the live event.
Veracyte (Nasdaq:VCYT) announced the U.S. commercial launch of its Prosigna Breast Risk of Recurrence (ROR) test for early-stage HR+ breast cancer, available to order starting June 8, 2026.
The genomic test estimates a patient’s 10-year distant recurrence risk and, according to Veracyte, predicts chemotherapy benefit, helping personalize treatment decisions. The company reports broad commercial payer coverage and financial assistance options.
Veracyte (Nasdaq:VCYT) reported ENZAMET Phase III data at ASCO 2026 showing its Decipher Prostate genomic test can identify which men with metastatic prostate cancer benefit from adding docetaxel to ADT plus enzalutamide.
In 634 patients (median follow-up 5.6 years), a significant treatment-by-biomarker interaction (p=0.043) provided Level 1B evidence. High Decipher scores (>0.85) with high-volume disease saw improved survival with triplet therapy, while low-score patients showed no added chemotherapy benefit. Additional pooled NRG/RTOG data in high-risk localized disease showed Decipher improved prognostic accuracy and reclassified about 1 in 4 patients, indicating more may benefit from ARPI-based treatment intensification.
Veracyte (Nasdaq:VCYT) reported Phase III OPTIMA trial results showing its Prosigna Breast Risk of Recurrence test can guide adjuvant chemotherapy decisions in early-stage, ER-positive, HER2-negative breast cancer.
The 4,429-patient study found 68% of clinically high-risk, node-positive patients could avoid chemotherapy with 5-year cancer-free survival of 93.7% versus 94.9% with chemotherapy.
Veracyte (Nasdaq:VCYT) will host an investor conference call and webcast on June 1, 2026 at 8:30 a.m. ET to discuss data from two phase III clinical trials using its Prosigna Breast and Decipher Prostate tests, including results from the OPTIMA and ENZAMET trials.
Professor Iain Macpherson will join the discussion. The live and replay webcasts will be accessible via Veracyte’s investor relations website.
Veracyte (NASDAQ:VCYT) will present new data from phase III OPTIMA and ENZAMET trials at the 2026 ASCO Annual Meeting. These studies evaluate how Prosigna Breast and Decipher Prostate genomic tests can guide chemotherapy and treatment intensification decisions in early breast cancer and metastatic prostate cancer.
Veracyte (Nasdaq:VCYT) will participate in two upcoming investor conferences. Management presents at the William Blair 46th Annual Growth Stock Conference in Chicago on June 2, 2026, and at the Jefferies Global Healthcare Conference in New York on June 4, 2026.
Both events feature live and replay webcasts via Veracyte’s investor relations site.